UCERIS Phase III Trial Data Introduced by Santarus

Santarus, Inc. introduced that in fact safety and efficacy data through a Phase III, double-blind, multicenter, placebo-controlled 12 month extensive use study together with the investigational medication UCERIS™ (budesonide) 6 mg tablets will be featured in four poster programs at the Digestive Disease Week (DDW®) Meeting being performed at the San Diego Convention Center on May 19 - 22, 2012.

A total of 123 affected individuals were enrolled within the extended use study that was undertaken to assess the long-term safety and tolerability of UCERIS 6 mg. The lengthy use study also explored the efficacy of UCERIS 6 mg within the maintenance of remission of ulcerative colitis when compared with placebo, but the learning was not powered to indicate statistical significance.